drugset / Trial / NCT00747669

Pharmacokinetic Study of Synera™ in Neonates and Infants

NCT00747669

Phase 4 Suspended 11 enrolled ZARS Pharma Inc.
NaSingle-groupOpen-labelBasic science

Summary

This study will measure the amount of lidocaine and tetracaine in the blood after a 30 minute application of Synera.

Timeline

Start
2008-09
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 70 mg Topical
Subject tetracaine Other / unclassified 70 mg Topical

Indications

No indication recorded.